Cunning cancer cells, such as melanoma and colorectal cancer, utilize the function of T-cell immune checkpoints (CTLA4) to suppress T-cell activation, thereby evading T-cell recognition and attack. PrecisemAb's Lock-CTLA4, once activated in diseased areas, binds to CTLA4 to maintain T-cell activation, thereby inhibiting cancer tumor growth.